💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vernakalant

CHEMBL2111112 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
349.5 g/mol
LogP
2.9
Phase
4

Vernakalant is an atrial-selective antiarrhythmic agent that blocks cardiac potassium channels (IKur, IKAch) and sodium channels preferentially in atrial tissue due to their higher firing rates, with minimal ventricular electrophysiological effects. It is used for the rapid pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm. Its atrial selectivity reduces the risk of ventricular proarrhythmia compared to non-selective antiarrhythmic agents.

分子量

349.5000 g/mol

LogP

2.90

TPSA

51.20 Ų

リピンスキーの五則

適合

治療領域

Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC

                

                

                
                

                    
InChI

                    
InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H31NO4

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
回転可能結合数

                        
7

                    

                    
                    
                    

                        
重原子数

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Vernakalant is an atrial-selective antiarrhythmic agent that blocks cardiac potassium channels (IKur, IKAch) and sodium channels preferentially in atrial tissue due to their higher firing rates, with minimal ventricular electrophysiological effects. It is used for the rapid pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm. Its atrial selectivity reduces the risk of ventricular proarrhythmia compared to non-selective antiarrhythmic agents.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Vernakalant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2111112.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9930049.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.